DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for congenital myasthenic syndrome 8 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCongenital myasthenic syndrome 8 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for congenital myasthenic syndrome 8 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
agrin (AGRN) — AGRN is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8S9P · 3.8 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
In a 2003 study of 16 unrelated patients with congenital myasthenic syndrome caused by rapsyn mutations, a common N88K mutation was identified. Two distinct phenotypes emerged: an early-onset form frequently associated with arthrogryposis multiplex congenita and life-threatening crises, and a late-onset form that developed in adolescence or adulthood and was initially mistaken for seronegative myasthenia gravis. The authors noted that recognition of the late-onset phenotype should prevent inappropriate immunotherapy.
A 2024 study from a single neurology department in Algiers reported on six patients carrying different CMS gene mutations, with different pathophysiologic profiles including slow and fast channel syndromes and low receptor expression. These patients were treated with innovative drugs normally indicated for non-neurological conditions, and the authors reported that their outcome was toward a clear clinical improvement. The study provides Class IV evidence, the lowest tier, meaning the findings are based on a small, uncontrolled case series with no comparator group.
Two review papers from 1999 and 2022 summarise that CMS are rare genetic disorders of neuromuscular junction signalling, that more than thirty pathogenic genes have been discovered, and that misdiagnosis and missed diagnosis are common. The 1999 review notes that pathogenesis remained elusive until the early 1990s, when molecular genetics and in vitro neurophysiology of intercostal muscle biopsies provided major insights. Neither review provides new clinical trial data specific to congenital myasthenic syndrome 8.
What is still missing: no randomised controlled trials exist for any drug specifically in congenital myasthenic syndrome 8; the 2024 case series is too small and uncontrolled to establish efficacy; no validated biomarkers or patient stratification criteria have been tested; and funding for prospective, genotype-stratified trials remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 2003 · 146 citations
Rapsyn mutations in hereditary myasthenia
AbstractRapsyn mutations in 16 unrelated patients with a congenital/hereditary myasthenic syndrome were identified, and a mutation (N88K) common to each of them was found. Two distinct phenotypes were noted: early and late onset. The former is frequently associated with arthrogryposis multiplex congenita and life-threatening crises. The late-onset phenotype developed in adolescence or adulthood and was initially mistaken for seronegative myasthenia gravis. Recognition of this late-onset phenotype should prevent inappropriate immunotherapy.
Neurology Clinical Practice · 2024 · 0 citations · open access
Innovative Therapeutic Approaches in Congenital Myasthenic Syndromes
AbstractBackground and Objectives: To provide real-word clinical follow-up data on patients carrying variations of congenital myasthenic syndromes (CMS) and who respond to some innovative drugs. Methods: Patients recruited from the Neurology Department of the Mustapha Bacha university hospital in Algiers. Treated with innovative drugs, they were monitored and their clinical progress was evaluated on the basis of clinical arguments suggestive of CMSs, but also para clinical arguments (electromyography and genetic study). Results: Six patients carrying different mutations in different genes of CMSs were studied. They had different pathophysiologic profiles (slow or fast channel syndromes, low expressor of receptor). Their therapeutic management was based on innovative drugs, normally indicated in other, non-neurological pathologies. Their outcome was toward a clear clinical improvement. Discussion: This work relates the interest of proposing treatments (outside of Pyridostigmine) in the management of CMSs. These therapies can greatly modify the prognosis of patients suffering from this orphan disease. Classification of Evidence: This study provides Class IV evidence that for patients with congenital myasthenic syndromes, some innovative treatments are effective.
DOAJ (DOAJ: Directory of Open Access Journals) · 2022 · 0 citations
Congenital Myasthenic Syndrome
AbstractCongenital Myasthenic syndrome (CMS) is a group of partially treatable genetic disorders characterized by dysfunction of neuromuscular junction signaling.With the popularization of high-throughput sequencing and in-depth understanding of the disease in recent years, more than thirty pathogenic genes have been discovered and there is a correlation between genotype and clinical phenotype.Misdiagnosis and missed diagnosis are common in clinical practice. This paper summarized the molecular mechanisms, clinical features, electrophysiologic, pathological features and treatment of main subtypes of CMS to deepen the understanding of the disease.
Recent Advances in Understanding Congenital Myasthenic Syndromes
AbstractCongenital myasthenic syndromes (CMS) are rare genetic disorders that continue to challenge the skills of clinical electrophysiologists, neuromuscular specialists, and general neurologists. Their pathogenesis remained elusive until the early 1990s, when advances in molecular genetics and in vitro neurophysiology of intercostal muscle biopsies provided major insights into disease mechanisms and created new ways to confirm …
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
